US · Healthcare

Insight Molecular Diagnostics Inc. (IMDX)

Diagnostics & Research

Insight Molecular Diagnostics Inc. (IMDX) is listed on US in the Healthcare sector. Industry: Diagnostics & Research. As of 2026-05-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for IMDX

P/E ratio

18.00

Insight Molecular Diagnostics Inc. (IMDX) — FAQ

What is IMDX's P/E ratio?

The price-to-earnings (P/E) ratio for Insight Molecular Diagnostics Inc. (IMDX) is 18.00 (data as of 2026-05-23).

Does Insight Molecular Diagnostics Inc. pay a dividend?

Dividend yield is not available in the current snapshot for Insight Molecular Diagnostics Inc. (IMDX). Check the MyAverix Finance app for the latest dividend data.

What sector is Insight Molecular Diagnostics Inc. in?

Insight Molecular Diagnostics Inc. (IMDX) is classified in the Healthcare sector (Diagnostics & Research industry).

What exchange is IMDX listed on?

IMDX is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)